Incontinence treatment Detrol had US sales of $571.5 million in the year to September 2013.
On Friday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced the launch in the US of an authorized generic version of Detrol. Detrol is an incontinence treatment produced by Pfizer. It has annual sales of approximately $571.5 million in the US, according to IMS data from September, 2013.
Teva has a market cap of $33.7 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013